

Michigan Pharmacy and Therapeutics Committee  
Cardiac Workgroup  
February 2009

Following discussion and review of the Cardiac drug classes on the Preferred Drug List, the workgroup recommends to the full Committee the following:

**ACE Inhibitors:** no changes to the current classification of drugs

**Antihypertensive Combinations: ACEI-CCB:** no changes to the current classification of Lotrel and Tarka; remove Lexxel from the list as it is no longer marketed

**Antihypertensive Combinations ARB-CCB:** no changes to the current classification of drugs

**Angiotensin Receptor Antagonists:** no changes to the current classification of drugs

**Direct Renin Inhibitors:** no changes to the current classification of Tekturna

**Beta Blockers:** no changes to the current classification of drugs; consider for Committee discussion creating a sub class of drug products for use in beneficiaries with congestive heart failure and post AMI; perform a DUR study to validate which drugs beneficiaries with the diagnosis of post AMI and/ or congestive heart failure are taking

**Calcium Channel Blockers-Dihydropyridine:** no changes to the current classification of drugs

**Calcium Channel Blockers-Non-dihydropyridine:** no changes to the current classification of drugs

**Lipotropic-Antihypertensive Combination:** no changes to Caduet

**Lipotropics-Non Statins: Fibrin Acid Derivatives:** no changes to the current classification of drugs

**Lipotropics-Non-Statins:** no changes to the current classification of drugs

**Lipotropics: Statins:** no changes to the current classification of drugs

**Lipotropics: Niacin derivatives:** no changes to the current classification of drugs

**Lipotropics; Other:** no changes to the current classification of drugs